WO2017021974A8 - Novel and synergistic composition of lecithin and lysolecithin for improving bioavailability and solubility of hydrophobic compounds and extracts - Google Patents

Novel and synergistic composition of lecithin and lysolecithin for improving bioavailability and solubility of hydrophobic compounds and extracts Download PDF

Info

Publication number
WO2017021974A8
WO2017021974A8 PCT/IN2015/000338 IN2015000338W WO2017021974A8 WO 2017021974 A8 WO2017021974 A8 WO 2017021974A8 IN 2015000338 W IN2015000338 W IN 2015000338W WO 2017021974 A8 WO2017021974 A8 WO 2017021974A8
Authority
WO
WIPO (PCT)
Prior art keywords
lysolecithin
lecithin
solubility
extracts
novel
Prior art date
Application number
PCT/IN2015/000338
Other languages
French (fr)
Other versions
WO2017021974A3 (en
WO2017021974A2 (en
Inventor
Ganga Raju Gokaraju
Rama Raju Gokaraju
Kiran Bhupathiraju
Trimurtulu Golakoti
Ravichandran Sripathy
Nirvanashetty Somashekara
Ramchand Nanappan Chaniyilparampu
Original Assignee
Laila Pharmaceuticals Pvt. Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laila Pharmaceuticals Pvt. Ltd. filed Critical Laila Pharmaceuticals Pvt. Ltd.
Priority to PCT/IN2015/000338 priority Critical patent/WO2017021974A2/en
Publication of WO2017021974A2 publication Critical patent/WO2017021974A2/en
Publication of WO2017021974A8 publication Critical patent/WO2017021974A8/en
Publication of WO2017021974A3 publication Critical patent/WO2017021974A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention discloses a composition(s) of hydrophobic plant molecule(s) and/or extract(s) with enhanced bioavailability comprising hydrophobic active and synergetic mixture of lecithin and lysolecithin and to the process for preparation thereof.
PCT/IN2015/000338 2015-08-31 2015-08-03 Novel and synergistic composition of lecithin and lysolecithin for improving bioavailability and solubility of hydrophobic compounds and extracts WO2017021974A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/IN2015/000338 WO2017021974A2 (en) 2015-08-31 2015-08-03 Novel and synergistic composition of lecithin and lysolecithin for improving bioavailability and solubility of hydrophobic compounds and extracts

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IN2015/000338 WO2017021974A2 (en) 2015-08-31 2015-08-03 Novel and synergistic composition of lecithin and lysolecithin for improving bioavailability and solubility of hydrophobic compounds and extracts

Publications (3)

Publication Number Publication Date
WO2017021974A2 WO2017021974A2 (en) 2017-02-09
WO2017021974A8 true WO2017021974A8 (en) 2018-03-08
WO2017021974A3 WO2017021974A3 (en) 2019-01-17

Family

ID=57944200

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2015/000338 WO2017021974A2 (en) 2015-08-31 2015-08-03 Novel and synergistic composition of lecithin and lysolecithin for improving bioavailability and solubility of hydrophobic compounds and extracts

Country Status (1)

Country Link
WO (1) WO2017021974A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018179011A1 (en) * 2017-03-29 2018-10-04 Olene Life Sciences Private Limited Composition to enhance bioavailability of natural compounds
CN110025604A (en) * 2019-04-11 2019-07-19 中国科学院西北高原生物研究所 Purposes of the hypericin in the Related product that preparation inhibits glucosidase activity
CN115813780A (en) * 2022-03-30 2023-03-21 广东格烯生物科技股份有限公司 Nano-scale yellow-dispelling composition containing tetrahydrocurcumin and preparation method thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8535750B2 (en) * 2005-05-17 2013-09-17 Cargill, Incorporated Granular lecithins, granular lysolecithins, process for their production and compositions containing them
US20080145411A1 (en) * 2006-10-06 2008-06-19 Kaneka Corporation Composition of high absorbability for oral administration comprising oxidized coenzyme q10
US8669241B2 (en) * 2008-12-02 2014-03-11 Rohto Pharmaceutical Co., Ltd. Ophthalmic composition
CN102762573B (en) * 2009-07-24 2015-09-16 阿马曾提斯公司 For protecting the compound of brain health, composition and method in neurodegenerative disorders
AU2013274105A1 (en) * 2012-06-14 2014-12-18 Signpath Pharma, Inc. Method and system for measuring the pharmacokinetics of liposomal curcumin and its metabolite tetrahydrocurcumin

Also Published As

Publication number Publication date
WO2017021974A3 (en) 2019-01-17
WO2017021974A2 (en) 2017-02-09

Similar Documents

Publication Publication Date Title
LT3577110T (en) 8-oxetan-3-yl-3,8-diazabicyclo[3.2.1]octan-3-yl substituted compounds as hiv inhibitors
WO2017106957A8 (en) Lipid-linked prodrugs
WO2016130920A3 (en) Lrrk2 inhibitors and methods of making and using the same
WO2015189346A8 (en) Novel material mixture containing rubusoside or alpha-glycosylrubusoside, for enhancing sweet taste
CO2018000793A2 (en) Adduct of (2e) -but-2-enedioic acid and- 3- (2 - {[4- (trifluoromethoxy) phenyl] amino} -1 - [(1r, 5r) -3,3,5-trimethylcyclohexyl] - acid 1h benzimidazol-5-yl) propanoic (1: 4) as inhibitor of the mutated isocitrate dehydrogenase idh1 r132h, methods for its preparation and compositions that comprise it
WO2015104658A3 (en) Amorphous solid dispersion of dapagliflozin and process for the preparation of amorphous dapagliflozin
EP4233556A3 (en) Sweet rapeseed protein isolate and process for obtaining it
WO2013134534A3 (en) Solid state forms of cabazitaxel and processes for preparation thereof
WO2015055706A3 (en) N-cycloalkyl-n-(biheterocyclymethylene)-(thio)carboxamide derivatives
WO2016125191A3 (en) Processes for the preparation of vortioxetine hydrobromide
WO2015092810A3 (en) Amorphous form of idelalisib
WO2016102420A3 (en) Novel isothiazolamides, processes for their preparation and their use as herbicides and/or plant growth regulators
WO2016199076A3 (en) Polymorphic forms of afatinib free base and afatinib dimaleate
WO2011122872A3 (en) Composition comprising coumestrol or a bean extract containing coumestrol
MX2019005855A (en) Powderous formulations.
PH12019500822A1 (en) Crystalline forms of eravacycline
EP3539550A4 (en) Pharmaceutical composition for preventing or treating neurodegenerative diseases which includes flower extract of daphne genkwa or fractions thereof as active ingredient
MY180844A (en) Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions
WO2016092561A3 (en) Novel polymorphs of ivacaftor, process for its preparation and pharmaceutical composition thereof
WO2016112875A3 (en) Diphenyl derivative and uses thereof
WO2017021974A8 (en) Novel and synergistic composition of lecithin and lysolecithin for improving bioavailability and solubility of hydrophobic compounds and extracts
SG10201907289VA (en) Monomethylfumarate prodrug compositions
IN2014CH00840A (en)
WO2016060935A3 (en) Compositions and methods of improving the digestibility of animal feed
WO2016005962A3 (en) Stable liquid formulations of cyclophosphamide and processes

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15900306

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15900306

Country of ref document: EP

Kind code of ref document: A2